Research Area:
pancreatic cancer; ovarian cancer; prostate cancer; bowel cancer; brain cancer; endometrial cancer; breast cancer; personalised medicine; high-throughput genomics

Link @ http://www.imb.uq.edu.au/sean-grimmond

Find more at http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1003107

Models and software for predicting who is at risk of carrying genetic variants that confer susceptibility to cancer. Application to breast, ovarian, colorectal, pancreatic and skin cancer.

Statistical methods for the analysis of high throughput genomic data: analysis of cancer genome sequencing projects; integration of genomic information across technologies; cross-study validation of genomics results.

Statistical methods for comparative effectiveness research: comprehensive models for lifetime history of chronic disease outcomes; Bayesian meta-analysis; Bayesian causal inference; decision analysis.

Bayesian modeling and computation: multilevel models; decision theoretic approaches to inference; sequential experimental design and their application to adaptive and multistage studies in clinical and epidemiological research.

http://bcb.dfci.harvard.edu/~gp/index.html

http://scholar.google.com/citations?user=OlpYP3UAAAAJ&hl=en

More @ http://www.bioinf.manchester.ac.uk/dbbrowser/index.php

The US born Sangeeta Bhatia at Massachusetts Institute of Technology (MIT) has developed a cheap, simple, paper test that can detect cancer. These diagnostic, which works much like a pregnancy test, could reveal within minutes, based on a urine sample, whether a person have cancer or not. The MIT media announce the major and amazing breakthrough in cancer diagonistics. These newly developed technology will allow non-communicable diseases to be detect at early stage, which will be cheap and easily accessible to the masses. For the developing world it would be exciting to adapt it instead to a paper test that could be performed on unprocessed samples in a rural setting, without the need for any specialized equipment. The simple readout could even be transmitted to a remote caregiver by a picture on a mobile phone.

The MIT professor and Howard Hughes Medical Institute investigator Sangeeta Bhatia, who is also the John and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science, invented a new class of synthetic biomarker, which is highly specialized instrument to do these kind of analysis. These paper test essentially relies on nanoparticles that interact with tumor proteins called proteases, each of which can trigger release of hundreds of biomarkers that are then easily detectable in a patient's urine. The MIT nanoparticles are coated with peptides (short protein fragments) targeted by different MMPs. These particles congregate at tumor sites, where MMPs cleave hundreds of peptides, which accumulate in the kidneys and are excreted in the urine.

To create the test strips, the researchers first coated nitrocellulose paper with antibodies that can capture the peptides. Once the peptides are captured, they flow along the strip and are exposed to several invisible test lines made of other antibodies specific to different tags attached to the peptides. If one of these lines becomes visible, it means the target peptide is present in the sample. The technology can also easily be modified to detect multiple types of peptides released by different types or stages of disease.

In tests in mice, the researchers were able to accurately identify colon tumors, as well as blood clots. Bhatia says these tests represent the first step toward a diagnostic device that could someday be useful in human patients. "This is a new idea — to create an excreted biomarker instead of relying on what the body gives you," she says. "To prove this approach is really going to be a useful diagnostic, the next step is to test it in patient populations."

Reference:

Image: jasongrowclients

Homepage: http://lmrt.mit.edu/about.html

http://web.mit.edu/newsoffice/2014/a-paper-diagnostic-for-cancer-0224.html

http://timesofindia.indiatimes.com/home/science/PIO-develops-cheap-paper-test-to-detect-cancer/articleshow/30963615.cms

More at http://www.tiehh.ttu.edu/dr.-kamaleshwar-singh.html

Duration of the Project: Six Months from the date of appointment can be extended further for six months
Essential Qualification and Experience: 1st Class Masters Degree in Bioinformatics or Life Sciences equivalent degree from a recognized University with 4 years R&D experience in Bioinformatics or relevant subjects from recognized institutes.
OR
Ph.D. degree in Bioinformatics or Life Sciences from recognized University.
M.Sc. degree obtained after a one year course will not be considered.
Experience: Research/teaching experience in Bioinformatics or relevant subjects form recognized Institute(s).

More at http://www.actrec.gov.in/data%20files/Vacancies/2016/AV-scin-stud-trainee-6-Sept-16.docx

Place of employment and work

The candidate will be located at the Department of Experimental Oncology of the European Institute of Oncology in Milan (Italy), one of Europe’s leading research institutes in biomedical research, where he/she will also interact with one of the largest computational biology communities in Italy

Requirements:

The candidate should have a good knowledge of the UNIX system and good programming skills (bash, R, python, java). Background in bioinformatics would be appreciated but is not mandatory. Additional experience with containers (docker, singularity), grid computing, web frameworks, continuous integrations will be appreciated.

For further info or to arrange an informal interview, please write to arnaud.ceol@ieo.it